resistant hypertension

Mineralys Therapeutics Publishes Phase 2 Explore-CKD Results Supporting Lorundrostat’s Potential in Kidney Disease

RADNOR, Pennsylvania, United States — October 28, 2026 Mineralys Therapeutics, Inc., a biopharmaceutical company developing treatments for hypertension and...

By cGxPwire Editor
October 29, 2026

.Clinical

Pentixapharm Advances PANDA Phase 3 Study After FDA Clearance

BERLIN, Germany – June 9, 2026 Pentixapharm Holding AG has achieved a major regulatory milestone after receiving U.S. Food...

By cGxPwire Editor
June 10, 2026

Bio-Pharma

Idorsia’s Aprocitentan Reduces Albuminuria in Resistant Hypertension

ALLSCHWIL, Switzerland, June 1, 2026 Idorsia Ltd announced new Phase 3 PRECISION study analyses showing that aprocitentan, its dual...

By cGxPwire Editor
June 1, 2026

MedTech

Japan Grants Insurance Coverage for Paradise uRDN System

TOKYO, Japan – March 1, 2026 Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that the...

By cGxPwire Editor
March 2, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

resistant hypertension

Mineralys Therapeutics Publishes Phase 2 Explore-CKD Results Supporting Lorundrostat’s Potential in Kidney Disease

Pentixapharm Advances PANDA Phase 3 Study After FDA Clearance

Idorsia’s Aprocitentan Reduces Albuminuria in Resistant Hypertension

Japan Grants Insurance Coverage for Paradise uRDN System